DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t3hhrz/investigation) has announced the addition of the "Investigation Report on China's Repaglinide Market, 2010-2019" report to their offering.
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.
Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide.
As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 2005-2014 reached about 22%.
Key Topics Covered:
1 Related Concepts of Repaglinide
2 Market Profile of Repaglinide in China
3 Survey on Sales Status of Repaglinide in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Repaglinide in China, 2010-2014
5 Survey on Dosage Forms of Repaglinide in China, 2010-2014
6 Reference Price of Repaglinide in Chinese Hospitals in 2014
7 Major Manufacturers of Repaglinide in Chinese Market, 2010-2014
8 Market Outlook of Repaglinide in China, 2015-2019
- Novo Nordisk A/S
- Hanson Pharmaceutical
- Tianjin Kangrui Pharmaceutical Co., Ltd
- Beijing Wansheng Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/t3hhrz/investigation